Skip to Main Content

Paper Details

UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12.
Br J Ophthalmol
44
2015
AMD, Diabetic Retinopathy, nAMD, neovascular AMD, neovascular age-related macular degeneration, patients, ranibizumab
Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Databases, Factual, Electronic Health Records, Female, Humans, Intravitreal Injections, Male, Middle Aged, Ranibizumab, Retreatment, United Kingdom, Vascular Endothelial Growth Factor A, Visual Acuity, Wet Macular Degeneration
Author NameAffiliation
Aaron LeeMoorfields Eye Hospital NHS Foundation Trust
Cecilia S LeeUniversity of Washington
Thomas ButtInstitute of Ophthalmology, University College London
Wen XingMoorfields Eye Hospital NHSFT
Robert L JohnstonCheltenham General Hospital
Usha Chakravarthy
Catherine EganMoorfields Eye Hospital NHS Foundation Trust
Toks AkereleHinchingbrooke Health Care NHS Trust
Martin McKibbinLeeds Teaching Hospitals NHS Trust
Louise DowneyHull and East Yorkshire Hospitals NHS Trust
Salim NathaWigan and Leigh NHS Foundation Trust
Clare BaileyBristol Eye Hospital
Rehna KhanCalderdale and Huddersfield NHS Foundation Trust
Richard J AntcliffRoyal United Hospital Bath NHS Trust
Atul VarmaMid Yorkshire Hospitals NHS Trust
Balakrishna Vineeth KumarWirral University Teaching Hospital NHS Foundation Trust
Marie D TsaloumasUniversity Hospitals Birmingham NHS Foundation Trust
Kaveri MandalWarrington and Halton Hospitals NHS Foundation Trust
Gerald LiewThe University of Sydney
Pearse A KeaneMoorfields Eye Hospital NHS Foundation Trust
Dawn A SimMoorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology
Catey BunceMoorfields Eye Hospital NHS Foundation Trust
Adnan TufailMoorfields Eye Hospital NHS Foundation Trust
  • 1 - 23

Datasets

Release 1.2